Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim N01 + ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia
NCT07586826Phase 2Recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Dec 2025
- Primary completion
- Oct 2027
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of romiplostim, tretinoin in chemotherapy-induced thrombocytopenia (CIT), sponsored by Peking University People's Hospital. Started Dec 2025; status: recruiting.
02
Drugs
romiplostimtretinoin
03
Conditions
chemotherapy-induced thrombocytopenia (CIT)
Beyond the preview
Go deeper on NCT07586826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07586826.